REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled TrialHuman Subjects

Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.

Irfan Hamza
Current problems in cardiology2024DOI: 10.1016/j.cpcardiol.2023.102060
SemaglutideGLP-1 receptor agonist

Quality Score

7/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for Semaglutide, GLP-1 receptor agonist are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for Semaglutide, GLP-1 receptor agonist. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Key Findings

The SELECT trial demonstrated a significant 20% reduction in major adverse cardiovascular events (MACE) for patients with obesity and cardiovascular disease who received semaglutide compared to placebo.

Limitations

While the study provides promising results, it does not fully explore potential long-term risks or side effects of semaglutide. Additionally, further research is needed to understand its benefits in diverse patient populations.

PeptideVault Analysis

Highlighting the groundbreaking potential of semaglutide in preventing major adverse cardiovascular events among patients with obesity and existing cardiovascular disease.

SemaglutideGLP-1 receptor agonist

Semaglutide Shows Promise in Reducing Heart Risks for Obese Patients with Cardiovascular Disease

Published: May 16, 2026 | Source: Current problems in cardiology (2024) | Category: Semaglutide, GLP-1 receptor agonist

Overview

A new study published in Current Problems in Cardiology reveals that semaglutide, a drug primarily used for weight loss and diabetes management, significantly reduces the risk of major adverse cardiovascular events among patients with obesity and pre-existing cardiovascular disease. This finding could mark a pivotal shift in how we manage heart risks associated with obesity.

Study Background

Cardiovascular diseases (CVD) are leading causes of death worldwide, often exacerbated by obesity through mechanisms like inflammation, insulin resistance, and altered lipid profiles. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to aid in weight loss and blood sugar control but its potential benefits for cardiovascular health were less understood until now.

The SELECT trial aimed to fill this gap by investigating whether semaglutide could reduce the risk of major adverse cardiovascular events (MACE), such as heart attacks or strokes, among obese patients with existing CVD. This double-blind, placebo-controlled study involved 17,604 participants and provided critical insights into the drug's cardiovascular benefits.

What the Research Found

The SELECT trial demonstrated that a weekly dose of 2.4 mg semaglutide led to a significant 20% reduction in MACE risk compared to a placebo group among patients with obesity and pre-existing CVD. This outcome underscores the potential for semaglutide not just as a weight management tool but also as an effective strategy to mitigate cardiovascular risks associated with obesity.

What This Means for Peptide Users

For individuals using peptides like GLP-1 receptor agonists, these findings suggest that semaglutide could offer additional cardiovascular benefits beyond its primary use in managing diabetes and obesity. However, it is crucial to consult healthcare providers before incorporating any new treatment regimen to ensure safety and efficacy.

Limitations and Caveats

While the SELECT trial offers compelling evidence of semaglutide's potential in reducing MACE risk, several limitations must be acknowledged. The study did not fully explore long-term risks or side effects associated with prolonged use of semaglutide. Additionally, further research is necessary to understand how this drug performs across diverse patient populations and in different clinical settings.

How This Compares to Previous Research

Previous studies have highlighted the benefits of GLP-1 receptor agonists like semaglutide in weight loss and diabetes management but their cardiovascular effects were less clear. The SELECT trial provides robust evidence supporting the use of semaglutide for reducing MACE risk, aligning with recent trends in cardiovascular research that emphasize the role of metabolic health in heart disease prevention.

Our Analysis

PeptideVault views this study as a significant advancement in understanding how GLP-1 receptor agonists like semaglutide can contribute to cardiovascular health. The 20% reduction in MACE risk is noteworthy and suggests potential clinical applications beyond weight loss and diabetes management. However, the limitations underscore the need for cautious interpretation and further investigation.

Key Takeaways

  • Semaglutide reduces major adverse cardiovascular events by 20% among obese patients with pre-existing CVD.
  • Further research is needed to understand long-term risks and benefits across diverse patient groups.
  • Consult healthcare providers before incorporating semaglutide into treatment plans for its potential cardiovascular benefits.

Original Source

Citation: Irfan Hamza (2024). Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial. Current problems in cardiology. DOI: 10.1016/j.cpcardiol.2023.102060

Access: https://pubmed.ncbi.nlm.nih.gov/37640171/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on Semaglutide, explore our research guides.

Citation

Irfan Hamza. (2024). Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.. Current problems in cardiology. https://doi.org/10.1016/j.cpcardiol.2023.102060

View full text on PubMed

Related Papers

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Misra Saurav et al. · Journal of basic and clinical physiology and pharmacology · 2025

Retatrutide-A Game Changer in Obesity Pharmacotherapy.

Katsi Vasiliki et al. · Biomolecules · 2025

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Rubino Domenica et al. · JAMA · 2021

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Rosenstock Julio et al. · Lancet (London, England) · 2021

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen Anders Boisen et al. · Obesity surgery · 2023

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.